This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
by Zacks Equity Research
Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
5 Stocks in Focus on New Analyst Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
Surging Earnings Estimates Signal Good News for Calithera Biosciences (CALA)
by Zacks Equity Research
Calithera Biosciences (CALA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Earnings Estimates Moving Higher for Calithera Biosciences (CALA): Time to Buy?
by Zacks Equity Research
Calithera Biosciences (CALA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Surging Earnings Estimates Signal Good News for Calithera Biosciences (CALA)
by Zacks Equity Research
Calithera Biosciences (CALA) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
Why Calithera Biosciences (CALA) Could Be Positioned for a Surge
by Zacks Equity Research
Calithera Biosciences (CALA) is seeing solid earnings estimate revision, and the stock is showing decent short-term momentum as well.
Calithera Biosciences (CALA) Jumps: Stock Moves 17% Higher
by Zacks Equity Research
Calithera Biosciences, Inc. (CALA) shares rise over 17% in the last trading session.
Zacks.com featured highlights: Calithera Biosciences, Weibo, Genco Shipping & Trading, Everi Holdings and Willdan Group
by Zacks Equity Research
Zacks.com featured highlights: Calithera Biosciences, Weibo, Genco Shipping & Trading, Everi Holdings and Willdan Group
Calithera Biosciences (CALA) Rises: Stock Moves Up 19.3%
by Zacks Equity Research
Calithera Biosciences, Inc. (CALA) shares rose over 19% in the last trading session.
Incyte and Calithera Enter into Deal for Oncology Candidate
by Zacks Equity Research
Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.
Is the Options Market Predicting a Spike in Calithera Biosciences (CALA) Stock?
by Zacks Equity Research
Investors in Calithera Biosciences, Inc. (CALA) need to pay close attention to the stock based on moves in the options market lately.
Calithera Biosciences (CALA) In Focus: Stock Jumps 46.7%
by Zacks Equity Research
Calithera Biosciences, Inc. (CALA) moved big last session, as its shares jumped almost 47% on the day.
Can The Uptrend Continue for Calithera Biosciences (CALA)?
by Zacks Equity Research
Investors certainly have to be happy with Calithera Biosciences, Inc. (CALA) and its short term performance
Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced a clinical trial collaboration with Calithera Biosciences, Inc. (CALA).